Table 2. Results of the studies included. The main results of the studies regarding the population characteristics, the main outcome (recurrence) and the secondary outcomes (adverse effects to treatment) are shown.
| Region | Reference | Daily PQ dose (mg/kg/day) | Duration PQ treatment (days) | Total PQ dose (mg/Kg) | Age (yrs) | Sex, percentage of men | Sample size | Length of follow-up (days) | Absolute recurrence frequency | % Cumulative recurrence incidence | Adverse effects |
|---|---|---|---|---|---|---|---|---|---|---|---|
| America | Pinto, et al 18 | 0.5 | 7 | 3.5 | rank 0 -15 | Not specified | 46 | 180 | 3 | 7,7 | Not specified |
| Abdon, et al 15 | 0.25 | 14 | 3.5 | mean 27 (IQR 12 - 67) | 60 | 40 | 180 | 2 | 5 | 27.5% from PQ standar regimen and 15.4% from PQ 0.5 mg/Kg/día/7 días. Diarrhea (5.8%). Sickness (5%). Pruritus (5%). Vomiting (1.7%). Epigastric pain (1.7%). Dizziness (0.8%). buzz (0.8%) | |
| 0.5 | 7 | 3.5 | 65 | 40 | 180 | 0 | 0 | ||||
| Solari-Soto, et al20 | 0.25 | 14 | 3.5 | mean 28.9 (SD 17.2) | 66.7 | 30 | 60 | 2 | 7 | Not reported | |
| 0.5 | 7 | 3.5 | mean 24.0 (SD 17.0) | 46.7 | 30 | 60 | 3 | 10 | |||
| Da Silva, et al 16 | 0.5 | 7 | 3.5 | mean 31.8 | 93.3 | 30 | 180 | 0 | 0 | Adverse effects were reported but not frequently specified in each arm, no differences between groups was reported. Pruritus 5.% and coluria 1.3% | |
| 0.5 | 7 | 3.5 | mean 33 | 66.7 | 30 | 180 | 1 | 3.3 | |||
| 0.5 | 7 | 3.5 | mean 36.9 | 83.3 | 30 | 180 | 5 | 16.7 | |||
| 0.5 | 7 | 3.5 | mean 36.6 | 70 | 30 | 180 | 1 | 3.3 | |||
| Carmona-Fonseca, et al 21 | 0.5 | 7 | 3.5 | rank 10 - 17 | Not specified | 41 | 120 | 8 | 22.8 | Sweating 11% . Conjunctival pallor8.7%. Diarrhea8.1%. Pruritus7.6%. Sickness 7.6%. Dizziness7.0%. Vomit 6.4%. Abdominal pain5.8%. Anorexia3.5%. | |
| Durand, et al 17 | 0.5 | 7 | 3.5 | mean 17.6 (rank 2-72) | 52.8 | 180 | 210 | 16 | 10.2 | Not reported | |
| 0.25 | 14 | 3.5 | mean 21.0 (rank 1-70) | 53.6 | 180 | 210 | 22 | 13.5 | |||
| Southeast Asian | Sutanto, et al 23 | 0.5 | 14 | 7 | mean 27.1 (IQR 22.1 - 31.5) | 100 | 39 | 365 | 7 | 19.4 | Not reported |
| 0.5 | 14 | 7 | mean 27.8 (IQR 23.6 - 42.1) | 100 | 36 | 365 | 2 | 5.6 | |||
| Rajgor, et al 19 | 0.25 | 14 | 3.5 | mean 31 (SD 12) | 94.9 | 398 | 180 | 26 | 8.1 | 5% | |
| 0.5 | 7 | 3.5 | mean 32 (SD 13) | 95.5 | 381 | 180 | 30 | 10.1 | 10% | ||
| 0.5 | 14 | 7 | mean 32 (SD 11) | 96.0 | 380 | 180 | 21 | 6.6 | 13% | ||
| Eastern Mediterranean | Leslie, et al 22 | 0.5 | 14 | 7 | meann 10 (IQR 4 - 45) | 44.0 | 55 | 330 | 1 | 1.9 | Not reported |
PQ, Primaquine, IQR, Interquartile range, SD, Standard deviation